Eli Lilly lifts 2026 revenue outlook as weight-loss drug demand surges, shares jump
Lilly's GLP-1 franchise drove another guidance raise, underscoring how obesity drugs are reshaping Big Pharma earnings even amid US pricing pressure.
Reuters · +14 outlets
Lilly's experimental triple agonist tops Novo's Ozempic in diabetes trial
The readout intensifies the race among next-generation multi-agonist obesity drugs, where Lilly and Novo are competing for the next standard of care.
BioPharma Dive · +14 outlets
India's NPPA cuts prices of 543 cancer drug brands by up to 93%, new rates effective Nov. 9
The revision leaves expensive branded oncology medicines largely untouched, reigniting debate over whether India's price controls deliver real affordability.
Hindustan Times · +14 outlets
Korea's first homegrown obesity drug Epe begins prescriptions, taking on Mounjaro and Wegovy
Hanmi Pharm's launch gives South Korea a domestically developed GLP-1 option priced below imported rivals, testing local demand for weight-loss treatment.
헤럴드경제 · +3 outlets
Agios says FDA extends review of its sickle cell drug to Feb. 1, 2027
The delay pushes back a potential new entrant in sickle cell disease, where competition among gene and drug therapies is already intense.
Stock Titan · +4 outlets
Vertex faces key FDA decision after RAINIER trial data
The regulatory test will shape Vertex's push beyond cystic fibrosis into pain and other new therapeutic areas.
ad-hoc-news.de · +2 outlets
Iovance shares fall after disappointing lung cancer trial data
The setback clouds the cell therapy developer's effort to expand its tumor-infiltrating lymphocyte platform beyond melanoma.
Yahoo Finance · +14 outlets
Ascletis oral GLP-1 hits Phase II diabetes endpoint as global obesity trials advance
An oral GLP-1 success would open a cheaper, pill-based alternative in a market dominated by injectables.
AllSci · +4 outlets
Korea's NPS shifts biotech bets toward K-beauty and obesity drugs
The pension fund's reallocation signals institutional conviction in obesity and cosmetics-adjacent biotech as growth themes.
Chosunbiz
Fractyl plans FDA filing for weight-loss maintenance procedure after drugs
The device maker aims to capture patients seeking durable results after stopping GLP-1 therapy.
Stock Titan · +14 outlets
Democratic win could trigger scrutiny of Trump's drug deals with Novo Nordisk
Midterm outcomes could reshape US drug pricing deals struck with major manufacturers.
MedWatch · +1 outlets
Big Pharma partners with AI firms to cut drug failures
Pharmaceutical companies are increasingly turning to AI to improve clinical trial success rates.
조선일보 · +14 outlets
India's Supreme Court questions NPPA's pricing oversight of drugmakers
Judicial scrutiny adds pressure to India's drug price regulator amid complaints of weak enforcement.
Medical Dialogues · +3 outlets
Five Massachusetts hospitals sue drug company over patient data
The suit spotlights growing legal risk over how drugmakers handle health information.
MassLive.com · +9 outlets
Pharma has friends in both parties this midterm season, but no free pass
Neither party appears poised to shield the industry from drug pricing pressure after the midterms.
Pharma Voice · +5 outlets
Dermata begins testing once-weekly acne treatment, eyes first-half 2027 launch
A less frequent topical regimen could differentiate in a crowded acne market.
Stock Titan · +1 outlets
Obesity drugs fuel a market before and after weight loss, spanning supplements and body contouring
Adjacent consumer and medical categories are expanding around the GLP-1 boom.
https://economy.ac/
West Pharma earnings show it's more than a GLP-1 play, analysts see upside
The packaging supplier's results reveal exposure beyond obesity drugs, diversifying its growth story.
CNBC